Could a shared antibody link two brain conditions?

NCT ID NCT06523296

This trial is taking on new participants right now.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This study investigates whether anti-AChR antibodies, found in the spinal fluid of people with myasthenia gravis, are associated with cognitive disorders. Researchers will compare antibody levels in stored spinal fluid and a fresh blood sample from adults with myasthenia and cognitive issues, as well as from Alzheimer's patients and healthy controls. The goal is to see if these antibodies might explain memory or thinking problems in myasthenia and whether they connect to Alzheimer's disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Analysis of anti-AChR antibodies in blood and cerebrospinal fluid (no drug or treatment given)
What this could lead to
If a link is found, it could point to a new way to understand or diagnose cognitive problems in myasthenia patients, and possibly clarify a connection to Alzheimer's disease.
What could go wrong
This is a small observational study (30 participants) that only looks at existing samples and one extra blood draw. It cannot prove cause and effect, and results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria For patient with myasthenia : 1. adult person, 2. Diagnosis of anti-AChR positive autoimmune myasthenia gravis, confirmed by clinical and biological data, and categorized in class I to IV according to the Myasthenia Gravis Foundation of America (MGFA) classification, 3. Mild or major neurocognitive disorder (DSM-5 criterion) having benefited from a diagnosis at the CMRR with CSF biomarker dosage and agreement to bio-collect residual CSF, 4. Agreeing to sign the free and informed consent, 5. Affiliate or beneficiary of a social security system. For patient with Alzheimer Disease : 1. adult person, 2. Mild or major neurocognitive disorder (DSM-5 criterion) having benefited from a diagnosis at the CMRR with CSF biomarker dosage and agreement to bio-collect residual CSF, 3. Neurocognitive disorder only linked to Alzheimer's disease (IWG-2 criterion): typical or atypical clinical form with biomarkers of Alzheimer's disease in the CSF; 4. Agreeing to sign the free and informed consent, 5. Affiliate or beneficiary of a social security system. For healty control : 1. absence of memory complaint, 2. absence of neurocognitive disorder, 3. Having agreed to carry out analyzes as part of research, on these CSF samples stored in the biobank of the Institute of Translational Neurology in Münster (Germany) Exclusion Criteria: For patient with myasthenia : 1. Person who does not have sufficient command of the French language to understand, read and write, to take neuropsychological tests; 2. Need to use the routine complementary CSF tube to carry out additional diagnostic explorations as part of routine care, 3. Vulnerable people are defined in articles L1121-5 to -8 ( Pregnant women, parturients and breastfeeding mothers, persons deprived of their liberty by a judicial or administrative decision, persons hospitalized without consent under articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of article L. 1121-8, and persons admitted to a health or social establishment for purposes other than research/Adults who are subject to a legal protection measure or who are unable to express their consent.), For patient with Alzheimer Disease : 1\) vulnerable people are defined in articles L1121-5 to -8 ( Pregnant women, parturients and breastfeeding mothers, persons deprived of their liberty by a judicial or administrative decision, persons hospitalized without consent under articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of article L. 1121-8, and persons admitted to a health or social establishment for purposes other than research/Adults who are subject to a legal protection measure or who are unable to express their consent.)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU de Nice

    RECRUITING

    Nice, Alpes Maritimes, 06000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.